RxDoctor Payments Data

Evelyne Mechas

Optometrist · Blue Ash, OHNPI 1114667227

Payments from drug & device makers

$6,262in general payments, 2019–2025

Across 89 payments — averaging $70.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Coopervision Inc.$2K
  • AbbVie$528
  • Bausch & Lomb Americas Inc.$486
  • Tarsus Pharmaceuticals, Inc.$451
  • Sun Pharmaceutical Industries Inc.$363
  • Johnson & Johnson Vision Care, Inc.$352
  • plus $2K from 10 others

What the payments were for

  • Travel & lodging$1,91131%
  • Food & beverage$4,35169%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,262 in reported general payments places this provider in the 90th percentile of 1,995 optometrist providers in Ohio.

See all optometrist providers in Ohio

Medicare billing

Part B allowed, 2024
$101,352
Medicare patients
508
Services billed
1,356

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost45$17,428
RestasisCyclosporine13$14,076
RhopressaNetarsudil Mesylate34$13,361
RocklatanNetarsudil Mesylat/Latanoprost18$6,573
CombiganBrimonidine Tartrate/Timolol15$5,373
Latanoprost384$3,534
SimbrinzaBrinzolamide/Brimonidine Tart13$3,439
Dorzolamide-TimololDorzolamide/Timolol/Pf18$2,559
Brimonidine Tartrate96$2,308
Prednisolone Acetate67$2,241
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat135$1,894
Bimatoprost12$1,612
Pilocarpine Hcl23$1,197
Travoprost14$1,169
Timolol Maleate124$1,050

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Combigan$528$36,87773 claims
AlconSimbrinza$323$3,43913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,995 optometrist providers in Ohio.

Other optometrist in Blue Ash

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →